logo
  Join        Login             Stock Quote

Mylan (MYL) PT Lifted To $26 By RBC Capital On Positive Developments, 'Outperform' Maintained

 May 16, 2012 04:29 PM
 


RBC Capital Markets analyst Shibani Malhotra increased her price target on shares of Mylan Inc. (NASDAQ:MYL) to $26 from $25 on recent positive developments, while maintaining "Outperform" rating.

The brokerage raised its Q3-2012 EPS estimate to $0.74 from $0.70, its Q4-2012 forecast to $0.71 from $0.68, its 2012 estimate to $2.50 from $2.43 and its 2013 forecast to $2.74 from $2.70.

Malhotra has increased 2012 EPS estimate for Mylan following the company's May 10 announcement increasing its 2012 EPS guidance to $2.45-$2.55 from previous forecast of $2.30-$2.50. Mylan also announced a $500 million share repurchase authorization.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

Contribution from generic Doryx 150mg (launched April 30). The analyst's previous estimate included a risk adjusted Doryx contribution in the second half of 2012; with the product now launched she has added it to her 2Q-2012 estimate and increased its contribution in the second half of 2012.

Risk adjusted generic Provigil launch in 3Q-2012. Mylan has challenged the FDA's decision to grant Teva FTF status, which was a reversal of the agency's initial determination that FTF status was shared among a number generic players including Mylan.

Teva's 180 day exclusivity expires one month into 4Q-2012, however if Mylan prevails the company will be able to enter the market earlier. To account for this Malhotra has added a risk adjusted contribution from generic Provigil (about $30 million) to her 3Q-2012 EPS estimate.

[Related -Mylan Inc (MYL): Patent Cliff Set To Fuel 200% Gain]

Given the continued strength of the franchise, Malhotra has slightly increased our sales estimate for the EpiPen product. She has reduced the minor impact from share repurchase to the bottom end of Mylan's 430-440 million share guidance to account for the company's new $500 million share repurchases authorization.

Malhotra continues to view Mylan as one of the best positioned generic companies on a fundamental basis given its broad global portfolio, low cost manufacturing and focus on quality and reliability. Her increased estimates drive price target up $1 to $26.

Mylan is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies.

MYL closed Wednesday's regular session up 0.28% at $21.28.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageIntegrated Device Technology Inc. (IDTI) Q1 Earnings Preview: Another Beat and Pop?

Integrated Device Technology Inc. (NASDAQ:IDTI) will issue first quarter 2015 financial results on July 28, read on...

article imageHerbalife Ltd. (NYSE:HLF) Q2 Earnings Preview: The Potential To Shock?

Herbalife Ltd. (NYSE:HLF) will release its second quarter 2014 financial results after the close of trading read on...

article imageHealth Net, Inc. (HNT): Potential to Be Huge Winners Says Bank of America

As of this keystroke, Health Net, Inc. (NYSE: HNT) shares are up around 4% on the day. The managed health read on...

article imageHomeAway, Inc. (AWAY) Q2 Earnings Preview: Top and Bottom Line Bullish Surprise?

HomeAway, Inc. (NASDAQ:AWAY) will report its financial results for the second quarter ended June 30, 2014 read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.